Axonal injury in multiple sclerosis

Current Neurology and Neuroscience Reports

Volumn 3, Issue 3, 2003, Pages 231-237

  Rammohan, Kottil W ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

AXONAL INJURY; CORRELATION ANALYSIS; DEMYELINATION; DISABILITY; HISTOPATHOLOGY; HUMAN; INFLAMMATION; MEDICAL RESEARCH; MOUSE; MULTIPLE SCLEROSIS; MYELIN SHEATH; NEUROLOGIC DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW; DEMYELINATING DISEASE; MYELINATED NERVE; NERVE DEGENERATION; NERVE FIBER; NERVE REGENERATION; PATHOLOGY; PHYSIOLOGY;

AXONS; DEMYELINATING DISEASES; DISABILITY EVALUATION; HUMANS; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NERVE FIBERS, MYELINATED; NERVE REGENERATION;

EID: 0038605526     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-003-0083-0     Document Type: Review

References (51)

1. Charcot M: Histologie de la sclerose en plaques. Gaz Hosp 1868, 554-558.
2. Ferguson B, Matyszak MK, Esiri MM, Perry VH: Axonal damage in acute multiple sclerosis lesions. Brain 1997, 120(Pt 3):393-399.
3. Trapp BD, Peterson J, Ransohoff RM, et al.: Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998, 338:278-285.
4. Laferriere NB, MacRae TH, Brown DL: Tubulin synthesis and assembly in differentiating neurons. Biochem Cell Biol 1997, 75:103-117.
5. Brady ST, Witt AS, Kirkpatrick LL, et al.: Formation of compact myelin is required for maturation of the axonal cytoskeleton. J Neurosci 1999, 19:7278-7288.
6. Kirkpatrick LL, Brady ST: Modulation of the axonal microtubule cytoskeleton by myelinating Schwann cells. J Neurosci 1994, 14:7440-7450.
7. Lycke JN, Karlsson JE, Andersen O, Rosengren LE: Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998, 64:402-404.
8. Sternberger LA, Sternberger NH: Monoclonal antibodies distinguish phosphorylated and nonphosphorylated forms of neurofilaments in situ. Proc Natl Acad Sci U S A 1983, 80:6126-6130.
9. Waxman SG: Conduction in myelinated, unmyelinated, and demyelinated fibers. Arch Neurol 1977, 34:585-589.
10. Waxman SG: Demyelination in spinal cord injury and multiple sclerosis: what can we do to enhance functional recovery? J Neurotrauma 1992, 9(suppl 1):S105-S117.
11. Meiri H, Baum Z, Rosenthal Y: Dynamic changes in sodium channels at demyelinated axons. Prog Neurobiol 1989, 32:159-179.
12. Noebels JL, Marcom PK, Jalilian-Tehrani MH: Sodium channel density in hypomyelinated brain increased by myelin basic protein gene deletion. Nature 1991, 352:431-434.
13. Novakovic SD, Levinson SR, Schachner M, Shrager P: Disruption and reorganization of sodium channels in experimental allergic neuritis. Muscle Nerve 1998, 21:1019-1032.
14. Shrager P: Sodium channels in single demyelinated mammalian axons. Brain Res 1989, 483:149-154.
15. Kornek B, Lassmann H: Axonal pathology in multiple sclerosis. A historical note. Brain Pathol 1999, 9:651-656.
16. Evangelou N, Esiri MM, Smith S, et al.: Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. Ann Neurol 2000, 47:391-395.
17. Evangelou N, Konz D, Esiri MM, et al.: Size-selective neuronal changes in the anterior optic pathways suggest a differential susceptibility to injury in multiple sclerosis. Brain 2001, 124:1813-1820.
18. Canter P, Prince C, Esiri MM: Spinal cord axonal loss in multiple sclerosis: a post-mortem study. Neuropathol Appl Neurobiol 1999, 25:459-467.
19. Lovas G, Szilagyi N, Majtenyi K, et al.: Axonal changes in chronic demyelinated cervical spinal cord plaques. Brain 2000, 123(Pt 2):308-317.
20. Davie CA, Silver NC, Barker GJ, et al.: Does the extent of axonal loss and demyelination from chronic lesions in multiple sclerosis correlate with the clinical subgroup? J Neurol Neurosurg Psychiatry 1999, 67:710-715.
21. Bitsch A, Schuchardt J, Bunkowski S, et al.: Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 2000, 123(Pt 6):1174-1183.
22. Rivera-Quinones C, McGavern D, Schmelzer JD, et al.: Absence of neurological deficits following extensive demyelination in a class I-deficient murine model of multiple sclerosis. Nat Med 1998, 4:187-193.
23. Ciccarelli O, Brex PA, Thompson AJ, Miller DH: Disability and lesion load in MS: a reassessment with MS functional composite score and 3D fast FLAIR. J Neurol 2002, 249:18-24.
24. Mainero C, De Stefano N, Iannucci G, et al.: Correlates of MS disability assessed in vivo using aggregates of MR quantities. Neurology 2001, 56:1331-1334.
25. Youl BD, Turano G, Miller DH, et al.: The pathophysiology of acute optic neuritis. An association of gadolinium leakage with clinical and electrophysiological deficits. Brain 1991, 114(Pt 6):2437-2450.
26. Harris JO, Frank JA, Patronas N, et al.: Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol 1991, 29:548-555.
27. McFarland HF, Frank JA, Albert PS, et al.: Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992, 32:758-766.
28. Barkhof F, Karas GB, van Walderveen MA: T1 hypointensities and axonal loss. Neuroimaging Clin North Am 2000, 10:739-752.
29. Paolillo A, Pozzilli C, Gasperini C, et al.: Brain atrophy in relapsing-remitting multiple sclerosis: relationship with 'black holes', disease duration and clinical disability. J Neurol Sci 2000, 174:85-91.
30. van Waesberghe JH, Kamphorst W, De Groot CJ, et al.: Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol 1999, 46:747-754.
31. Arnold DL, Riess GT, Matthews PM, et al.: Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann Neurol 1994, 36:76-82.
32. Arnold DL, Wolinsky JS, Matthews PM, Falini A: The use of magnetic resonance spectroscopy in the evaluation of the natural history of multiple sclerosis. J Neurol Neurosurg Psychiatry 1998, 64(suppl 1):S94-S101.
33. Arnold DL: Magnetic resonance spectroscopy: imaging axonal damage in MS. J Neuroimmunol 1999, 98:2-6.
34. De Stefano N, Matthews PM, Narayanan S, et al.: Axonal dysfunction and disability in a relapse of multiple sclerosis: longitudinal study of a patient. Neurology 1997, 49:1138-1141.
35. De Stefano N, Matthews PM, Fu L, et al.: Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain 1998, 121(Pt 8):1469-1477.
36. De Stefano N, Narayanan S, Matthews PM, et al.: In vivo evidence for axonal dysfunction remote from focal cerebral demyelination of the type seen in multiple sclerosis. Brain 1999, 122(Pt 10):1933-1939.
37. De Stefano N, Narayanan S, Mortilla M, et al.: Imaging axonal damage in multiple sclerosis by means of MR spectroscopy. Neurol Sci 2000, 21:S883-S887.
38. De Stefano N, Narayanan S, Francis GS, et al.: Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 2001, 58:65-70.
39. Fu L, Matthews PM, De Stefano N, et al.: Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 1998, 121(Pt 1):103-113.
40. Matthews PM, De Stefano N, Narayanan S, et al.: Putting magnetic resonance spectroscopy studies in context: axonal damage and disability in multiple sclerosis. Semin Neurol 1998, 18:327-336.
41. Narayanan S, Fu L, Pioro E, et al.: Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions. Ann Neurol 1997, 41:385-391.
42. Narayanan S, De Stefano N, Francis GS, et al.: Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol 2001, 248:979-986.
43. Newman TA, Woolley ST, Hughes PM, et al.: T-cell- and macrophage-mediated axon damage in the absence of a CNS-specific immune response: involvement of metalloproteinases. Brain 2001, 124:2203-2214.
44. Kapoor R, Davies M, Smith KJ: Temporary axonal conduction block and axonal loss in inflammatory neurological disease. A potential role for nitric oxide? Ann N Y Acad Sci 1999, 893:304-308.
45. Redford EJ, Kapoor R, Smith KJ: Nitric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible. Brain 1997, 120(Pt 12):2149-2157.
46. Smith KJ, Kapoor R, Felts PA: Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol 1999, 9:69-92.
47. Smith KJ, Hall SM: Factors directly affecting impulse transmission in inflammatory demyelinating disease: recent advances in our understanding. Curr Opin Neurol 2001, 14:289-298.
48. Charles P, Reynolds R, Seilhean D, et al.: Re-expression of PSA-NCAM by demyelinated axons: an inhibitor of remyelination in multiple sclerosis? Brain 2002, 125:1972-1979.
49. Coulson-Burghes S, Rammohan KW: Experimental axonal ion channel encephalitis [abstract]. Ann Neurol 1999, 46:456-456.
50. Coulson-Burghes S, Rammohan KW, Gonzales LM: Inflammatory infiltrates in experimental axonal ion-channel encephalitis [abstract]. Neurology 2000, 54:A125.
51. Smith KJ, Kapoor R, Hall SM, Davies M: Electrically active axons degenerate when exposed to nitric oxide. Ann Neurol 2001, 49:470-476.